Brivanib

Description: Brivanib / BMS-540215 is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β and in Phase 3.

• Catalog: OFC649735466
• CAS: 649735-46-6
• Category: Fluorinated APIs
• Synonyms: BMS-540215
• Purity: >98%

• IUPAC Name: (2R)-1-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol
• InChI: InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
• InChI Key: WCWUXEGQKLTGDX-LLVKDONJSA-N
• Isomeric SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OC[C@@H](C)O)C
• EC Number: 639-685-1

• Molecular Formula: C19H19FN4O3
• Molecular Weight: 370.38
• Appearance: White to off-white solid powder

• XLogP3-AA: 3
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 5
• Exact Mass: 370.14411864 g/mol
• Monoisotopic Mass: 370.14411864 g/mol
• Topological Polar Surface Area: 84.7Ų
• Heavy Atom Count: 27
• Formal Charge: 0
• Complexity: 515